https://www.biospace.com/article/releases/boston-scientific-launches-vercise-genus-dbs-system-in-europe/
Boston Scientific Launches Vercise Genus™ DBS System In Europe
Published: Sep 09, 2020
MARLBOROUGH, Mass., Sept. 9, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe. Featuring full-body MRI conditional1 and Bluetooth capabilities across the portfolio, the Vercise Genus System is indicated to treat the symptoms of Parkinson’s disease (PD), essential tremor, and dystonia by delivering precisely targeted electrical stimulation in the brain designed to provide optimal symptom relief.
